Please login to the form below

Not currently logged in
Email:
Password:

GLP-1

This page shows the latest GLP-1 news and features for those working in and with pharma, biotech and healthcare.

Pricing pressures peg back Lilly’s growth products

Pricing pressures peg back Lilly’s growth products

That scenario also applied to Trulicity – the first once-weekly GLP-1 agonist to reach the market – which rose 30% to $880m.

Latest news

  • Novo Nordisk and Gilead join forces in NASH Novo Nordisk and Gilead join forces in NASH

    It recently filed a new oral formulation of semaglutide with the FDA, and hopes a speedy review will culminate in the first GLP-1 agnostic pill approved to treat diabetes.

  • Novo uses voucher for speedy answer on oral semaglutide Novo uses voucher for speedy answer on oral semaglutide

    Known for now as oral semaglutide, the once-daily glucagon-like peptide-1 (GLP-1) analogue tablet is highly anticipated, as its patient-friendly formulation could see it dominate in the ... s older daily GLP-1 treatment Victoza as the biggest seller in

  • Trulicity’s ascent lifts Lilly Trulicity’s ascent lifts Lilly

    The once-weekly GLP-1 analogue is the company’s rising star, and was boosted in November when it unveiled compelling new cardiovascular outcomes data from its REWIND study. ... year. That means 2019 could see Trulicity overtake its rival, though Novo

  • Novo Nordisk preps for speedy oral GLP-1 drug filing Novo Nordisk preps for speedy oral GLP-1 drug filing

    Novo is claiming that Ozempic’s launch has “stabilised” its GLP-1 market share at around 26%. ... 10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone.

  • FDA adcomm split on Sanofi’s type 1 diabetes drug FDA adcomm split on Sanofi’s type 1 diabetes drug

    The panel voted eight to eight when asked if the overall benefits of Zynquista (sotagliflozin) outweighed its risks as an add-on to insulin treatment for adult patients with type 1 ... as stimulate the release of GLP-1.

More from news
Approximately 12 fully matching, plus 137 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    These efforts moved up a gear last year when Novo decided to enter into phase III trials with an oral GLP-1.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    like peptide-1 (GLP-1), a hormone that works independently of insulin to stimulate glucose release. ... Oramed - whose technology relies on encapsulating the peptide or protein and delivering it alongside enzyme inhibitors and permeation enhancers - has

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... 6, 546. Hanmi Pharmaceutical. Sanofi. Licence. Three diabetes

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    400. Inarcia therapeutics / Investors. Synthetic royalty rights. ICTA650 extended sub-cutaneous delivery of GLP-1 for T2DM.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics